Matériels et Méthodes

Données sur les cohortes

Cohorte PEGAN
\

&@
=A.&7A@
.7"5B@
%7@
"&A
&@@.
9BF&?AZ
"97A?:5(
&A
?7%96.@(
(A.&7A
,(@
%&
v}

|z
7@
&A
AA&.7A@
%_B7&
-(=A.A&

"-?97.>B&
F&"
%&@
7A.,'7&@
&
7(,A.+@]
5@
=?(@&7A.&7A
B7&
"-?,&
F.?5&
7(,A.F&
=9B?
5_
%&

&A
97A
(A(
A?.A(@
=&7%7A
B
69.7@
B7
7
=?
759,B&@
7B"5(9@jAk.%.>B&@
%7@
A?9.@
@&?F."&@
%&
@9.7@
A&?A..?&@
&7
-(=A959,.&
&7
?7"&]
&@
"?.A'?&@
%_.7"5B@.97
(A.&7A
\

• 7&
"97"&7A?A.97
&7

.7+(?.&B?&
9B
(,5&

".7>
+9.@
5
5.6.A&
79?65&
@B=(?.&B?&
• 7&
"97"&7A?A.97
%7@
5&
@(?B6
%&
5_5=-
+9&A9=?9A(.7&
.7+(?.&B?&

zu7,d6

• 7
A&@A
%&
,?9@@&@@&
7(,A.+
=9B?
5&@
+&66&@]

&@
"?.A'?&@
%_&H"5B@.97
(A.&7A
\

• 7&
"97A?&f.7%."A.97
=9B?
5&
 f
• ?(@&7"&
%_B7


&@
=A.&7A@
97A
(A(
?(=?A.@
5(A9.?&6&7A
%7@
%&BH
,?9B=&@
9)
B7&
5.@A&
,(7(?(&
.7+9?6A.>B&6&7A
F&"
@A?A.+."A.97
=?
5&B?
A.A?&
&7
7A.,'7&@
@]
&
=?&6.&?
,?9B=&

?&$B
B7&
.73&"A.97
@9B@f"BA7(&
%&
v}u‡,
%&
 f
=?
@&6.7&
=&7%7A
y}
@&6.7&@
&7
=5B@
%&
5&B?
A?.A&6&7A
=?
%&@
759,B&@
7B"5(9@jAk.%.>B&@]
&
%&BH.'6&
,?9B=&

"97A.7B(
%&
?&"&F9.?
5&B?
A?.A&6&7A
=?
%&@
759,B&@
7B"5(9@jAk.%.>B&@
@&B5&6&7A]
9B?
"->B&
=A.&7A
%&
79A?&
(AB%&Z
B7&
=?&6.'?&
!.9=@.&

(A(
?(5.@(&
5&
39B?
%&
5_.7"5B@.97
&A
B7&
@&"97%&
~{
@&6.7&@
=?'@
5&
%(!BA
%&
5_&@@.
"5.7.>B&
j9B?5.'?&
&A
5]
wuv|k
j.,B?&
{yk]
Cohorte de patients traités par la Telbivudine :

&AA&
"9-9?A&

"96=?(
%&BH
,?9B=&@
%&
=A.&7A@
\

• 7
=?&6.&?
,?9B=&
%&
z{
=A.&7A@
F&"
B7&
6979f.7+&"A.97
=9B?
5_-(=A.A&

"-?97.>B&
A?.A(@
=?
5
&5!.FB%.7&
=&7%7A
x

z
7@]
&@
%977(&@
"5.7.>B&@
&A
F.?959,.>B&@
97A
(A(
"955&"A(&@
B
%(!BA
%&
5_(AB%&
&A

5
+.7
%&
5_(AB%&]
&@
!.9=@.&@
%&
"&@
=A.&7A@
97A
(A(
?(5.@(&@

5
+.7
%&
5_(AB%&
=B.@
5&@
("-7A.5597@
97A
(A(
"97,&5(@
=9B?
&++&"AB&?
5&@
75I@&@
%_
&A
%_]

vz}
• 7
%&BH.'6&
,?9B=&
%&
y{
=A.&7A@
>B.
97A
(A(
.7"5B@
?(A?9@=&"A.F&6&7A
%7@
5
"9-9?A&]
&@
=A.&7A@
(A.&7A
@B.F.@
=9B?
B7&
-(=A.A&

"-?97.>B&
@7@
"9f.7+&"A.97

5_-:=.A5
B7.F&?@.A.?&
%&
I97]
B
696&7A
%&
5
!.9=@.&Z
B"B7
%_&7A?&
&BH
7&
?&"&F.&7A
%&
A?.A&6&7A
7.
7_F.&7A
(A(
A?.A(&@
7A(?.&B?&6&7A]
&@
!.9=@.&@
-(=A.>B&@
%&
"&
,?9B=&
97A
(A(
&++&"AB(&@
=9B?
%&@
.7%."A.97@
"5.7.>B&@
&A
B7&
=?A.&
%&@
("-7A.5597@
97A
(A(
"97,&5(@
=9B?
)A?&
BA.5.@(&@
%7@
%&@
?&"-&?"-&@
=?'@
5_9!A&7A.97
%B
"97@&7A&6&7A
%&@
=A.&7A@]
&
=?9A9"95&

(A(
==?9BF(
=?
5&
"96.A(
(A-.>B&
%&
I97
j.,B?&
{zk]

Cohorte de transplantés hépatiques de l’hôpital de Beaujon :

&@
=A.&7A@
%&
"&AA&
"9-9?A&
97A
!(7(+.".(
%_B7&
A?7@=57AA.97
-(=A.>B&
=9B?
A?.A&?
B7&
.7+&"A.97
=?
5&
Z

5_-:=.A5
%&
&B397
&7A?&
v~~}
&A
wuvx]&@
,?&++&@
-(=A.>B&@
97A
(A(
?(5.@(&@
@9.A
%7@
B7
"97A&HA&
%&
".??-9@&@
F&"
9B
@7@

@9.A
%7@
5&
"%?&
%_B7&
-(=A.A&
+B56.77A&]
&@
!.9=@.&@
97A
(A(
?(5.@(&@
5&
39B?
%&
5
A?7@=57AA.97
&A
B7
7
=9@A
A?7@=57AA.97]

7A?&
v~~}
&A
wuu~Z
5
=?(F&7A.97
"97A?&
5
?(.7+&"A.97
=?
5&

(A.A
?(5.@(&
=?
B7&
"96!.7.@97
%_759,B&@
%&
7B"5(9@jAk.%.>B&@
F&"
B7
A?.A&6&7A

597,
A&?6&
=?
%&@
.66B79,59!B5.7&@
]

=?A.?
%&
wuu~Z
F&"
5_??.F(&
%_759,B&@
%&
7B"5(9@jAk.%.>B&@
%&
@&"97%&
,(7(?A.97
j&7A("F.?
&A
A(79+9F.?kZ
5
6(A-9%&
%&
=?(F&7A.97

(A(
"-7,(&]
&
A?.A&6&7A
=?
759,B&@
%&
7B"5(9@jAk.%.>B&@

(A(
%(!BA(
.66(%.A&6&7A
=?'@
5
A?7@=57AA.97
&A
@_&@A
=9B?@B.F.
%&
+$97
.7%(A&?6.7(&Z
5&@
.66B79,59!B5.7&@

97A
(A(
%6.7.@A?(&@
=&7%7A
|
39B?@
@&B5&6&7A]
9B?
"&AA&
"9-9?A&Z
A?&7A&fA?9.@
!.9=@.&@
97A
(A(
75I@(&@
j.,B?&
{{k]

Extraction d’ADN et ARN des échantillons de biopsie

_
&A
5_
97A
(A(
&HA?.A@

=?A.?
%&@
!.9=@.&@
"97,&5(&@
%&
+9.&@
-B6.7@]
&@
("-7A.5597@
%&
+9.&
97A
%_!9?%
(A(
-969,(7(.@(@
%7@
%&
5
,5"&
F&"
5&
b
.@@B&
?B=A9?
c
jB.,&7k
%7@
B7
A6=97
%_-969,(7(.@A.97
j

=}
zu7
[

v6Z

vzu6k
=B.@
%.F.@(@
&7
A?9.@
=.'"&@
=9B?
=?9"(%&?

5_&HA?"A.97
&A
5
=B?.+."A.97
%&
5_
&A
%&
5_
?&@=&"A.F&6&7A
&A
5
-]
=?'@
B7&
%.,&@A.97
=?
5
=?9A(.7@&
Z
5_

(A(
&HA?.A
9)
5&
4.A
b
@A&??&
c
j=."&7A?&k
&7
@B.F7A
5&@
?&"9667%A.97@
%B
+!?."7A]
_
5B.

(A(
&HA?.A
&7
BA.5.@7A
5&
4.A
b
B"5(9@=.7
9A5

7%
=?9A&.7
.@95A.97
c
j"-&?&If,&5k]
7&
+9.@
5_&HA?"A.97
+.A&Z
5_

(A(
?(A?9A?7@"?.=A
&7

vz~
BA.5.@7A
5&
4.A
%&
5
b
@B=&?@"?.=A

c
j-&?69
.@-&?k]
7&
=?A.&
%&
5_

(A(
%.,(?(&
=?
5

=9B?
5
>B7A.+."A.97
%&
5_"""]
_
&A
5_
97A
&7@B.A&
(A(
>B7A.+.(@
=?
5
A&"-7.>B&
%&
>
9B
%%]

Quantification ADN et ARN par qPCR


>B7A.+."A.97
%&
5_
9B
%&
5_
%B


(A(
&++&"AB(&

=?A.?
%_B7
A-&?69"I"5&B?
>B7A.AA.+
j==5.&%
.9@I@A&6k]

A?7@"?.=A.97
.7F&?@&
%&
5_
%B


(A(
?(5.@(&

=?A.?
%B
=?9A9"95&
%B
4.A
%&
5
b
B=&?@="?.A

c
j-&?69
.@-&?k]

?("A.97
%&
>
@&
+.A
F&"
%&@
69?"&@
&A
B7&
@97%&
>67
%97A
5&@
@(>B&7"&@
@97A
5.@A(&@
%7@
5&
A!5&B
y]
&@
69?"&@
@97A
@=(".+.>B&@
?&@=&"A.F&6&7A
=9B?
5_"""Z
&A
5_=,
%97A
5
@(>B&7"&

(A(
%=A(&

=?A.?
%&
5
=B!5."A.97
%&
95J
&A
.]

9B?
F9.?
B7
796!?&
%&
"9=.&@
%&
=?A."B5&@
F.?5&@
=?
"&55B5&@Z
5_"""
&@A
79?65.@(
F&"
5&
,'7&
%&
5
Uf,59!.7&
%97A
5
>B7A.+."A.97
&@A
?(5.@(&
&7
%B=5&H]

_=,
&@A
79?65.@(
=?
?==9?A

B7
,'7&
%&
6(7,&Z
B@Z
=9B?
=&?6&AA?&
%&
+.?&
5_75I@&
?&5A.F&
%B
,'7&
F.?5]
&@
69?"&@
%&
5
Uf,59!.7&Z
%&
B@!
&A
%&
5_?"
%B

@97A
%&@
69?"&@
+9B?7.&@
=?
.+&
&"-7959,.&@]

&@
%.5BA.97@
&7
@(?.&
97A
(A(
&++&"AB(&@
F&"
5&
=5@6.%&
=
xww
=9B?
5
,66&
@A7%?%
557A
%&
vu^|
"9=.&@

vu^w
"9=.&@]
&@
?("A.97@
%&
>
97A
(A(
?(5.@(&@
@&597
5&@
"I"5&@
%("?.A@
%7@
5&
A!5&B
z
&A
{]

Quantification ADN et ARN par ddPCR


>B7A.+."A.97
%&
5_
&A
5_
%B


(A(
?(5.@(&
F&"
5&
vuuq
?9=5&A
.,.A5q

I@A&6
j.9f%Z
&?"B5&@Z
Z
k
@&597
5&@
.7@A?B"A.97@
%B
+!?."7A]
?.'F&6&7AZ
wz
V
%&
5
?("A.97
%&
%%
"96=?&7%
%B
B=&?6.H
w
%%
j.9f%Z
5&@7A97Z
Z
kZ
~uu
7695d
%&
6(57,&
%_69?"&@
F&"
B7&
@97%&
j%97A
5&@
@(>B&7"&@
@97A
?(+(?&7"(&@
%7@
5&
A!5&B
yk
&A
z
V
%&
6A?."&
%_
9B
%_
%&
5_("-7A.5597

>B7A.+.&?]


=5>B&

(A(
&7@B.A&
%(=9@(&
%7@
5_BA96A&
,(7(?A&B?
%&
,9BAA&5&AA&@
jBA9 k
F&"
5&@
"97@966!5&@
7("&@@.?&@
=9B?
=&?6&AA?&
5&
=?A.A.977&6&7A
%&
5_("-7A.5597

wu
uuu
,9BAA&5&AA&@
&7F.?97]

&A
BA96A&
BA.5.@&
5
6."?9+5B.%.>B&
>B.
=&?6&A
5_(6B5@.97
&7A?&
5_-B.5&
&A
5&@
("-7A.5597@Z
=9B?
,(7(?&?
%&@
,9BAA&@
%&
5
A.55&
%_B7
7795.A?&
?&"9667%(&
=9B?
5_75I@&
&7
%%]

=5>B&
%&


(A(
&7@B.A&
@"&55(&
F&"
B7
+.56
=&?$!5&
F.
vq

v{u

=5A&
@&5&?
j.9f%Z
&?"B5&@ZZ
k
&A
5_6=5.+."A.97

(A(
?(5.@(&

5_.%&
%B
A-&?69"I"5&B?
vuuu
9B"-q%&&=fG&55
j.9f%Z
&?"B5&@Z
Zk]

_6=5.+."A.97
=?


(A(
?(5.@(&
F&"
5&
=?9A9"95&
%("?.A
%7@
5&
A!5&B
|]

=5>B&

(A(
&7@B.A&
?&+?9.%.&

yr]
=?'@
5_6=5.+."A.97Z
5
=5>B&

(A(
=5"(&
%7@
5&
5&"A&B?
vuu
?9=5&A
&%&?
j.9f%Z
&?"B5&@Z
Z
k]
&
@.,75
%&
+5B9?&@"&7"&
%&@
,9BAA&@

(A(
75I@(

5_.%&
%B
59,.".&5
B7A9+Aq
75I@.@
@9+AG?&
F&?@.97v]|
j.9f%Z
&?"B5&@Z
Z
k]

&BH
7.F&BH
%&
+5B9?&@"&7"&@
%.++(?&7A@
97A
(A(
F.@B5.@(@
"9??&@=97%7A
B
"5B@A&?
=9@.A.+
j=?(@&7"&
%_6=5.+."A.97k
&A
B
"5B@A&?
7(,A.+
j!@&7"&
%_6=5.+."A.97k]
7
@&B.5
%&
+5B9?&@"&7"&
%977(

(A(
+.H(
=9B?
5_&7@&6!5&
%&@
("-7A.5597@
=&?6&AA7A
%&
@(=?&?
"&@
%&BH
"5B@A&?@]

"97"&7A?A.97
!@95B&
%&
"->B&
("-7A.5597
&@A
BA96A.>B&6&7A
"5"B5(&
=?
5&
59,.".&5
%&
%%
&7
"5"B57A
5&
?A.9
%&@
,9BAA&5&AA&@
=9@.A.F&@
@B?
5&
796!?&
%&
,9BAA&5&AA&@
A9A5&@
"96!.7(
F&"
5
59.
%&
9.@@97]

Chromatine immunoprécipitation (µChIP)

9B?
5&
b
"?9@@f5.74.7,
cZ
5
!.9=@.&

(A(
6.@&
%7@
%B

vH
F&"
%B
+9?65%-(-I%&
vƒ
&A
.7"B!(&
z
6.7

A&6=(?AB?&
6!.7A&]

?("A.97
%&
b
"?9@@f5.74.7,
c

(A(
??)A(&
=?
B7&
@95BA.97
%&
,5I".7&

5
"97"&7A?A.97
+.75&
%&
u]vwz]
&@
("-7A.5597@
97A
(A(
5F(@
%&BH
+9.@
F&"
%B

+?9.%
&A
"&7A?.+B,(@

y|u,
=&7%7A
vu
6.7

yr]
&@
("-7A.5597@
=&BF&7A
)A?&
@A9"4(@

"&AA&
(A=&

f}ur]

=?'@
5&@
(A=&@
%&
5F,&Z
5&@
("-7A.5597@
97A
(A(
?&f@B@=&7%B@
%7@
B7
A6=97
%&
@97."A.97
j
vƒ
[

vu
6
[

g
=}
zu6k
=B.@
97A
(A(
.7"B!(@
z
6.7
%7@
%&
5
,5"&]
&@
("-7A.5597@
97A
(A(
&7@B.A&
A?.A(@
%7@
5&
@97."A&B?
=&7%7A
%&BH
"I"5&@
%&
xu
@&"97%&@
b
97
c
&A
xu
@&"97%&@
b
9++
c
=B.@
97A
(A(
"&7A?.+B,(@
=&7%7A
vu
6.7

yr

vw
uuu,]
&
@B?7,&7A

(A(
=?(5&F(
&A
B7&
79BF&55&
"&7A?.+B,A.97

(A(
&++&"AB(&
=&7%7A
vu
6.7

yr

vw
uuu,]
&
@B?7,&7A

(A(

79BF&B
?("95A(
&A
6.@
F&"
5&
=?&6.&?
@B?7,&7A
=?(5&F(
=9B?
B7
79BF&B
"I"5&
%&
@97."A.97
&A
B7&
79BF&55&
"&7A?.+B,A.97

(A(
&++&"AB(&
=&7%7A
vu
6.7

yr

vw
uuu,]
B.@
5
"-?96A.7&

(A(
.7"B!(&
F&"
5&@
7A."9?=@
7A.f w|"
jx‡,kZ
7A.f z{"
jz‡,kZ
7A.f4~6&x
jx‡,kZ
7A.
w|6&x
jx‡,k
=&7%7A
B7&
7B.A

yr]
&
5&7%&6.7Z
5&@
("-7A.5597@
97A
(A(
5F(@
>BA?&
+9.@

5_.%&
%&
=9?A9.?
6,7(A.>B&
F&"
%B

"97A&77A
%B

&A

=B.@
F&"
%B
A6=97
%_(5BA.97
j?.@f
=
|]z

wu6
[

z6
[
5
zu6
[

vƒ
[
?9A(.7@&

zu‡,
&A

vk]
&@
("-7A.5597@
97A
(A(
.7"B!(@
=&7%7A
w-

{}r

vxuu
?=6
F7A
5_&HA?"A.97
B
=-(795
"-59?9+9?6&
.@96I55"9-95]

v{v




!"

807)&) 7)10
35
!!
"7
4
!"
.P
"7
.P3'
!06
!"6
)136)"6
($37)48"6
O
807)&) 7)10
!"
.G
"0
13)"6
35
4807)7$
!G
35
!!
"7
4F
O
807)&) 7)10
!"
.G3'
"0
13)"6
35
4807)7$
!G
35
!!
"7
4F
O
9.87)10
!"
.G 7)9)7$
7506 5)37)100".."
!"
.G
35
.
/"685"
!8
57)1
"075"
.G3'
"7
.G F





!#
807)&) 7)10
35
!!
!"
.P
"7
!"
.G3'
!06
."6
)136)"6
($37)48"6
!"
(48"
37)"07
0.<6$F


155"6310!

.
)136)"
&)7"
."
,185
!"
.G)0 .86)10F
\Y
155"6310!

\Y
6"/)0"6
35#6
."
!$87
!"
.G$78!"
O
807)&) 7)10
!"
.G
"0
13)"6
35
4807)7$
!GF
O
807)&) 7)10
!"
.G3'
"0
13)"6
35
4807)7$
!GF
O
9.87)10
!"
.G 7)9)7$
7506 5)37)100".."
!"
.G
35
.
/"685"
!8
57)1
!"
.G3'
"7
.G F

v{w

3 Résultats

Evaluation de l’ADNccc et de son activité transcriptionnelle dans la cohorte PEGAN :

9B?
"&AA&
"9-9?A&
y
=A.&7A@
I7A
&B
B7&
=.?&
%&
!.9=@.&@
97A
(A(
(AB%.(&@
F&"
%&BH
=A.&7A@
%7@
"->B&
,?9B=&]
&@
!.9=@.&@
97A
(A(
75I@(&@
&7
%%
&A
>
=9B?
5
>B7A.+."A.97
%&
5_"""
&A
5_=,]
&@
("-7A.5597@
(A7A
+.!5&6&7A
"97"&7A?(@Z
@&B5&
5
A&"-7.>B&
&7
%%

=&?6.@
%_9!A&7.?
%&@
?(@B5AA@
j+.,B?&
{|k]
_&7@&6!5&
%&@
?(@B5AA@
=?
>
97A
(A(
7(,A.+@]
_75I@&
&7
%%

"97+.?6(
5
=?(@&7"&
%&
5_"""
%7@
"&@
("-7A.5597@
%&
!.9=@.&@
.7@.
>B&
5
=?(@&7"&
%&
5_=,]

=?(@&7"&
%&
5_=,
.7%.>B&
%97"
>B&
5_"""
&@A
=?(@&7A
&A
A?7@"?.=A.977&55&6&7A
"A.+]
9B?
(F5B&?
@97
"A.F.A(Z
79B@
F97@
&H=?.6(
5&
?A.9
%&
5
"97"&7A?A.97
%&
5_=,
@B?
5
"97"&7A?A.97
%&
5_"""]
.7@.Z
97
=&BA
"97@AA&?
>B&
6)6&
@.
5_"""
&@A
=?(@&7AZ
@97
"A.F.A(
A?7@"?.=A.977&55&
?&@A&
=&B
(5&F(&]

_(F95BA.97
%B
ABH
%&
5_"""
&A
%&
5_=,
&7A?&
5
=?&6.'?&
&A
5
%&BH.'6&
!.9=@.&
97A
(A(
&7@B.A&
=?(@&7A(&
=9B?
"->B&
=A.&7A
j+.,B?&
{}k]
B"B7&
"97"5B@.97
7&
=&BA
)A?&
+.A&
@B?
5_&++&A
%&@
A?.A&6&7A@Z
"96=A&
A&7B
%B
+.!5&
796!?&
%&
=A.&7A@]
7
=&BA
@.6=5&6&7A
"97@AA&?
>B&
A9B@
5&@
=A.&7A@
97A
B7
ABH
%&
"""
%(A&"A!5&
%7@
5&@
%&BH
,?9B=&@]
&=&7%7AZ
97
=&BA
?&6?>B&?
>B&
5_B7
%&@
=A.&7A@

=?(@&7A(
B7&
B,6&7AA.97
%&
5_"""
59?@
>B_B7
BA?&
=A.&7A
I7A
&B
B7
A?.A&6&7A
%.++(?&7A

=?(@&7A(
B7&
B,6&7AA.97
%&
5_=,
&7A?&
5
=?&6.'?&
&A
5
%&BH.'6&
!.9=@.&]
&AA&
B,6&7AA.97
=&BA
@_&H=5.>B&?
=?
B7
!..@
%_("-7A.55977,&
59?@
%B
=?(5'F&6&7A
%&
5
!.9=@.&]

Evaluation de l’ADNccc et de son activité transcriptionnelle dans la cohorte de patients traités par la Telbivudine

7@
"&AA&
"9-9?A&
z{
=A.&7A@
A?.A(@

5
&5!.FB%.7&
&A
yw
=A.&7A@
"97A?:5&@
97A
(A(
75I@(@
+.7
%_(F5B&?
5
>B7A.A(
%_"""Z
%&
5_=,
&A
5_"A.F.A(
A?7@"?.=A.977&55&
%&
5_"""]

_75I@&
%&
5_"""

(A(
?(5.@(&
=?
5
A&"-7.>B&
%&
>Z
%&

&A
%&
%%
=9B?
++.7&?
79A?&
6(A-9%&
%&
%(A&"A.97]

"96=?.@97
%&
"&@
%.++(?&7A&@
6(A-9%&@

=&?6.@
%&
697A?&?
B7&
6&.55&B?&
@&7@.!.5.A(
%&
%(A&"A.97
=?
5
%%]
7
"97@AA&
.7@.

v{x


!$  1/35)610
!"
.
!$7" 7)10
!"
.G
35
.
7" (0)48"
!"
4C
!"

"7
!"
!!
!06
."
'5183"
!"
37)"076
75)7$6
35
.
".)98!)0"
"7
."
'5183"
10752."F
0.<6"
!"
.0!
.7/0
9.)!07
.
10 15!0 "
!"
.
!!
"7
4
3185
.
4807)&) 7)10
!"
.G F


"

807)&) 7)10
35
!!
!"
.P
"7
35
4
!"
.G3'
!06
."6
)136)"6
($37)48"6F

&597
5&
,?9B=&
%&
=A.&7A@
A?.A(@
=?
&5!.FB%.7&
&A
5&
,?9B=&
"97A?:5&]
O
807)&) 7)10
!"
.G
"0

13)"6
35
01<8
35
!!
"0
&10 7)10
%&@
%&BH
,?9B=&@F
O
807)&) 7)10
5".7)9"
!"
.G3'
35
4
"0
&10 7)10
%&@
%&BH
,?9B=&@F
O
155"6310!0 "
"075"
.
4807)&) 7)10
!"
.G3'
"0
&10 7)10
!"
.
4807)&) 7)10
!"
.G
("=
37)"076
010
75)7$6F
!O
155"6310!0 "
"075"
.
4807)&) 7)10
!"
.G3'
"0
&10 7)10
!"
.
4807)&) 7)10
!"
.G
("=
37)"076
75)7$6
35
.
".)98!)0"F

1 2 3 -5 0 5 1 0 1 5 2 0 2 5 8 1 0 1 2 1 4 M o y e n n e Di ff é r e n c e





v{y
>B&
=9B?
5&@
=A.&7A@
797
A?.A(@Z
zzƒ
%&@
=A.&7A@
(A.&7A
=9@.A.+@
=9B?
5_"""
&7
>]
?6.
5&@
yzƒ
%&
=A.&7A@
7(,A.+@
&7
>Z
{|ƒ
97A
(A(
=9@.A.+@
&7
"""
=?
5
A&"-7.>B&
%&

&A
}}ƒ
97A
(A(
=9@.A.+@
=?
5
A&"-7.>B&
%&
%%]


6)6&
9!@&?FA.97
=&BA
)A?&
+.A&
"-&J
5&@
=A.&7A@
A?.A(@]
7
"97@AA&
>B&Z
xuƒ
%&@
=A.&7A@
(A.&7A
=9@.A.+@
=9B?
5_"""
&7
>]
?6.
5&@
|uƒ
%&
=A.&7A@
7(,A.+@
&7
>Z
y|ƒ
97A
(A(
=9@.A.+@
&7
"""
=?
5
A&"-7.>B&
%&

&A
}~ƒ
97A
(A(
=9@.A.+
=?
5
A&"-7.>B&
%&
%%]
7

B@@.
697A?(
B7&
6&.55&B?&
%(A&"A.97
%&
5_"""
=?
%%]
7
=&BA
79A&?
>B&
5&
=9B?"&7A,&
%&
%(A&"A.97
%&
5_"""
&@A
5&
6)6&
=9B?
5&@
=A.&7A@
A?.A(@
&A
797
A?.A(@]
j.,B?&
{~k]
_75I@&
%&
57%
5A67

=&?6.@
%&
"96=?&?
5
%%
&A
5
>]
.7@.
97
"97@AA&
5
"97"9?%7"&
&7A?&
5&@
%&BH
A&"-7.>B&@
@B?A9BA
=9B?
5&@
=5B@
+.!5&@
F5&B?@]

B
7.F&B
>B7A.AA.+Z
97

"97@AA(
B7&
%.6.7BA.97
@.,7.+."A.F&
%&
5_"""
&A
%&
5_=,]
+.7
%_(F5B&?
5_"A.F.A(
A?7@"?.=A.977&55&
%&
5_"""
"-&J
"&@
=A.&7A@Z
B7&
%?9.A&
%&
"9??(5A.97
&7A?&
5_=,
&A
5_"""

(A(
(A!5.A
"-&J
5&@
=A.&7A@
"97A?:5&
&A
5&@
=A.&7A@
A?.A(@
=?
5
&5!.FB%.7&]
7
"97@AA&
.7@.
B7&
=&?A&
%&
5
"9??(5A.97
&7A?&
5_=,
&A
5_"""
"-&J
5&@
=A.&7A@
A?.A(@
=?
5
&5!.FB%.7&
=?
?==9?A
BH
=A.&7A@
"97A?:5&]
j.,B?&
|uk]

9B?
"96=?&7%?&
"&AA&
=&?A&
%&
"9??(5A.97
>B&
5_97
=&BA
9!@&?F&?
"-&J
5&@
=A.&7A@
A?.A(@Z
%&@
75I@&@
%&
-Z
@B?
|
=A.&7A@
%B
,?9B=&
"97A?:5&
&A
@B?
vu
=A.&7A@
%B
,?9B=&
A?.A(@
I7A
&B
5&
6&.55&B?
ABH
%_"""Z
97A
(A(
?(5.@(&@
F&"
%&@
7A."9?=@
?&"977.@@7A
5&@
69%.+."A.97@
=9@A
A?%B"A.977&55&@
%&@
-.@A97&@]
.7@.Z
97

=B
"97@AA&?Z
5
=?(@&7"&
%_&7?."-.@@&6&7A
%&
6?>B&@
?(=?&@@.F&@
@B?
5_"""
"-&J
5&@
=A.&7A@
A?.A(@
"96=?(
B
"97A?:5&
@B,,(?7A
B7&
%.6.7BA.97
%&
5
A?7@"?.=A.97
%&
5_"""
j.,B?&
|vk]
7&
%&@
-I=9A-'@&@
@&?.A
>B&
5
=?(@&7"&
%&
5
&5!.FB%.7&
%("5&7"-&
%&@
6("7.@6&@
%&
?(=?&@@.97@
+.7
%_.7-.!&?
(,5&6&7A
5
+9?6A.97
%&@

F.?BH
&A
%97"
%&@
=?A."B5&@
@B!F.?5&@]

v{z


"

9.87)10
!"
.G 7)9)7$
7506 5)37)100".."
!"
.G
35
(
O
0.<6"6
!"
.G C
685
!8
/7$5)".
H
5166.)0-$6
I
3519"007
!"6
)136)"6
($37)48"6
!06
."6
37)"076
75)7$6
35
".)98!)0"
"7
010
75)7$6F
G0.<6"

$7$
"&&" 78$"
"0
87).)607
!"6
07) 1536
1075"
."6
/1!)&) 7)106
3167
75!8 7)100".."6
!"6
()6710"6F
O
."8
!$7"5/)007
."6
/1!)&) 7)106
3167
75!8 7)100".."6
!"6
()6710"6
661 )$"6

80"
7506 5)37)10
0$'7)9"6
18
316)7)9"
!"
.G F

"
807)&) 7)10
35
!!
"7
4
!"
.P
"7
.P3'
!06
."6
)136)"6
($37)48"6F
O
10 "0757)10
!"
.G
"0
13)"6
35
01<8F
"6
10 "0757)106
6107
!$7" 7."6
80)48"/"07
"0
!!F
O
5)7)10
!"
.
4807)7$
!G3'
N1.!
(0'"O
"0
&10 7)10
!G80
'#0"
!"
/$0'"
"..8.)5"
N86OF

1 2 3 4 5 6 7 8 9 _{1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0 2 1 2 2 2 3 2 4 2 5 2 6 2 7 2 8 2 9 3 0 3 1 3 2 3 3} 0 .0 0 0 0 1 0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 H B V c c c D N A B io p s ie s n u m b e r C o n c e n tr at io n ( C o p ie s /n u cl eu s) d d P C R  

 

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 0 2 0 4 0 6 0 A R N p g Q u an ti té r e la ti ve d 'A R N p g d d P C R q P C R 


v{{

Evaluation sur l’ADNccc et de son activité transcriptionnelle dans la cohorte de transplantés hepatique de l’hôpital de Beaujon

_75I@&
%&@
("-7A.5597@
%&
"&AA&
"9-9?A&

(A(
?(5.@(&
&7
F&B,5&Z
@7@
"9770A?&
5&
,?9B=&
BH>B&5@
.5@
==?A.&77&7A]
9B?
5_""""Z
A9B@
5&@
?(@B5AA@
&7
>
97A
(A(
.7%(A&"A!5&@]
9B?
5
%%Z
wx
("-7A.5597@
97A
(A(
>B7A.+.!5&@
=9B?
5_"""
&A
vu
("-7A.597@
97A
(A(
.7%(A&"A!5&
=9B?
5_"""]
?
"97A?&Z
5_=,

(A(
%(A&"A(
=?
5&@
%&BH
A&"-7959,.&@
"96=A&
A&7B
%&@
"97"&7A?A.97@
=5B@
(5&F(&@
"&A
]

=?(@&7"&
%&
5_=,
@B,,'?&
>B&
5_"""Z
6)6&
&7
+.!5&
>B7A.A(Z
&@A
A?7@"?.=A.977&55&6&7A
"A.+
j.,B?&
|wk]

B?
5&@
xx
("-7A.5597@
75I@(@
=?
%%
&A
>Z
5&@
"9??(5A.97@
F&"
5&@
%977(&@
"5.7.>B&@
97A
(A(
%.@=97.!5&@
=9B?
w{
("-7A.5597@
@&B5&6&7A]
&@
75I@&@
+.A&@
=?
5&@
"5.7.".&7@
%&
5_(AB%&
97A
(,5&6&7A
697A?(
>B_.5
7_I
F.A
=@
%&
%.++(?&7"&
&7A?&
5&@
=A.&7A@
I7A
?&$B
5&
A?.A&6&7A
=?
,
7A.@

597,
A&?6&
jwu
("-7A.5597@k
=?
?==9?A
BH
=A.&7A@
I7A
?&$B
5&
A?.A&6&7A
=?
,
7A.@

"9B?A
A&?6&
j{
("-7A.5597@k]
&
=5B@Z
.5
@&6!5&?.A
>B_.5
7_I

=@
%&
%.++(?&7"&@
@B?
5&@
=?6'A?&@
F.?BH
&7
+97"A.97
%B
@AABA
%&@
7A."9?=@
7A.f"
7A.,'7&@
%B
%977&B?]

v{|

4 Discussion

"AB&55&6&7AZ
5&@
A&"-7.>B&@
%&
>B7A.+."A.97
%&
5_"""
7&
@97A
=@
@@&J
@&7@.!5&@
=9B?
%(A&"A&?
%&
+.!5&
>B7A.A(
%7@
"&A

%7@
%&@
("-7A.5597@
+.!5&6&7A
"97"&7A?(@
"966&
5&@
!.9=@.&@]
&
67>B&
%&
A&"-7959,.&
7&
=&?6&A
=@
%_(F5B&?
&A
%_&@A.6&?
"9??&"A&6&7A
5&@
&++&A@
%&@
A?.A&6&7A@]

B
"9B?@
%&
"&AA&
A-'@&Z
5&
=?&6.&?
H&
%&
?&"-&?"-&

=&?6.@
%&
6&AA?&
B
=9.7A
5
A&"-7.>B&
%&
%%
=9B?
5
>B7A.+."A.97
%&
5_"""]
9B@
F97@
697A?(
>B&
"&AA&
A&"-7.>B&
=&?6&AA.A
B7
,.7
%&
5
@&7@.!.5.A(
%&
%&BH
59,
=?
?==9?A

5
>]

%.@"B@@.97
%&
"&A
H&
@&
=9?A&?
=?.7".=5&6&7A
@B?
%&@
@=&"A@
A&"-7.>B&@]
&@
@=&"A@
!.959,.>B&@
&A
"5.7.>B&@
@&?97A
!9?%(@
%7@
5
%.@"B@@.97
,(7(?5&]

9B@
F97@
BA.5.@(
5
%%
=9B?
(F5B&?
5&@
=?6'A?&@
F.?BH
%7@
A?9.@
"9-9?A&@
%&
!.9=@.&@
%.++(?&7A&@]
9@
?(@B5AA@
97A
697A?(
>B&
5&@
6.@&@
B
=9.7A
&++&"AB(@
%7@
5&
=?&6.&?
H&
(A.&7A
@B++.@7A&@
=9B?
=&?6&AA?&
5
>B7A.+."A.97
%&
5_"""
&A
%&
5_=,
%7@
%&@
("-7A.5597@
%&
!.9=@.&@]
B"B7&
6.@&
B
=9.7A
@B==5(6&7A.?&
7_
(A(
7("&@@.?&]
.
5
"96=9@.A.97
%&
5_("-7A.5597
"5.7.>B&Z
7.
5&@
"97%.A.97@
%&
@A9"4,&
%&
"&@
("-7A.5597@
7_97A
.7A&?+(?(
%7@
5_6=5.+."A.97
%&@
".!5&@]

9@
?(@B5AA@
97A
697A?(
>B&
5
@=(".+.".A(
%&
5
>
&A
%&
5
%%
(A.A
.%&7A.>B&
=B.@>B&
79B@
F97@
=B
9!A&7.?
5&@
6)6&@
?(@B5AA@
@B?
5
>B7A.+."A.97
%&
5_=,
%7@
5
%&?7.'?&
"9-9?A&
%&
=A.&7A@]
_75I@&
%&
5_"""
%7@
"&@
"9-9?A&@
"97+.?6&
(,5&6&7A
5
6&.55&B?&
@&7@.!.5.A(
%&
5
%%
=?
?==9?A

5
>]
B?
5&@
!.9=@.&@
75I@(&@Z
5
%(A&"A.97
%&
5_"""
=?
>

(A(
=9@@.!5&
%7@
@&B5&6&7A
x{ƒ
%&@
("-7A.5597@
%&
5
%&BH.'6&
"9-9?A&]

>B7A.+."A.97
%&
5_"""
%7@
5&@
BA?&@
("-7A.5597@

(A(
9!A&7B&
B7.>B&6&7A
&7
%%Z
"?
.5@
(A.&7A
&7
5.6.A&
%&
%(A&"A.97
%&
5
>]

&
=5B@Z
B7&
6&.55&B?&
@&7@.!.5.A(
%&
5
%%
=?
?==9?A

5
A&"-7.>B&


(A(
%(697A?(&
%7@
5_(AB%&
%&
5
@&"97%&
"9-9?A&]
9B@
F97@
697A?(
B7&
B,6&7AA.97
%&
5
@&7@.!.5.A(
%&
wuƒ
%7@
5
%(A&"A.97
%&
5_"""]
5
&@A
.6=9?A7A
%&
"97@AA&?
>B&
"&
=9B?"&7A,&
%&
%(A&"A.97
&A
%_B,6&7AA.97
%&
@&7@.!.5.A(
7_&@A
=@
++&"A(
=?
5&
A?.A&6&7A

597,
A&?6&]

v{}
_75I@&
%&
"&@
"9-9?A&@
"97+.?6&
5_BA.5.@A.97
%&
5
%%
&7
%&BH.'6&
.7A&7A.97]
7
&++&AZ
5_!@&7"&
%&
,.7
&7
@=(".+.".A(
=9B?
%&@
+9?A&@
"97"&7A?A.97@
&A
5_B,6&7AA.97
%&
5
@&7@.!.5.A(
=9B?
%&@
+.!5&@
"97"&7A?A.97@
=&?6&AA&7A
%&
=?9=9@&?
5_BA.5.@A.97
%&
5
>
=9B?
.%&7A.+.&?
5&@
("-7A.5597@
+.!5&6&7A
"97"&7A?(@
&A
%_==5.>B&?
5
%%
B7.>B&6&7A
=9B?
"&@
("-7A.5597@]
&".
=?(@&7A&?.A
B7
.7A(?)A
&7
A&?6&
%&
A&6=@
&A
%&
"9DA]
&=&7%7AZ
"&?A.7&@
5.6.AA.97@
@97A
&7"9?&

=?&7%?&
&7
"96=A&]
?&6.'?&6&7AZ
"&?A.7@
("-7A.5597@
@97A
&7"9?&
7(,A.+@
&7
%%Z
79A66&7A
%7@
5
%&?7.'?&
"9-9?A&
(AB%.(&]
&@
?(@B5AA@
697A?&7A
B7&
!@&7"&
%&
%(A&"A.97@
%&
5_"""
59?@
>B_97
%(A&"A&
%&
5_=,
%7@
"&@
6)6&@
("-7A.5597@]
&BH
-I=9A-'@&@
=&BF&7A
)A?&
+.A&@
\

• 
=?&6.'?&
-I=9A-'@&
&@A
>B_.5
&H.@A&
B7&
5.6.A&
%&
%(A&"A.97
%&
5_"""
=?
5
%%]
9B?
6(5.9?&?
5
@&7@.!.5.A(Z
5
A&"-7.>B&
%&
%(A&"A.97
=?
(F'7&6&7A@
??&@
=9B??.A
)A?&
&7F.@,(&]
&=&7%7AZ
&55&
7("&@@.A&
B7
F95B6&
%_("-7A.5597
.6=9?A7A]

• 
@&"97%&
-I=9A-'@&
&@A
>B&
5&
A?.A&6&7A
=?
5


(A(
A?9=
%(5(A'?&
=9B?
5_"""
&7A?.77A
@97
(5.6.7A.97]
7
&++&AZ
5&@
"97%.A.97@
%&
@A9"4,&
%&@
!.9=@.&@Z
5&@
"I"5&@
%&
"97,(5A.97
&A
%&
%("97,(5A.97
.7@.
>B&
5&@
"97%.A.97@
%&
A?7@=9?A@
=&BF&7A
5A(?&?
"&?A.7@
("-7A.5597@
5&@
?&7%7A
=5B@
@&7@.!5&

5
@&]
&BH.'6&6&7AZ
"966&
(F9>B(
%7@
5_H&
vZ
"&AA&
>B7A.+."A.97
&@A
%(=&7%7A&
%_B7&
@&
>B.

B7
&++&A
=9@@.!5&
@B?
5
%(A&"A.97
%&@
+BH
7(,A.+@
&A
%&@
+BH
=9@.A.+@]
7
&++&AZ
5_BA.5.@A.97
%_B7&
@&
7&
=&?6&A
=@
%&
@&
%(+.?&

vuuƒ
%&
=9@@.!5&
"97A6.7A.97
=?
5_?"]

@=(".+.".A(
%&
5
A&"-7.>B&
%(=&7%7A
(,5&6&7A
%&
5_&++."".A(
%&
5_&7JI6&]

5,?(
"&@
5.6.A&@Z
5
%%
==9?A&
B7
F7A,&
"97@.%(?!5&
=9B?
5
%(A&"A.97
%&
5_"""
%7@
%&@
!.9=@.&@
%&
=A.&7A@
A?.A(@]
55&
=&?6&A
%&
6.&BH
(F5B&?
5_&++."".A(
%&@
A?.A&6&7A@
&A
"97+.?6&
5
7("&@@.A(
%&
%(F&59==&?
%&
79BF&55&@
@A?A(,.&@
A-(?=&BA.>B&@]

v{~

5 Article

&@
?(@B5AA@
%&
5
"9-9?A&
%&@
=A.&7A@
A?.A(@
=?
5
A&5!.FB%.7&
97A
=&?6.@
5_("?.AB?&
%_B7&
=B!5."A.97
&7
"97"9?%7A
5&@
%977(&@
"5.7.>B&@
&A
F.?959,.>B&@
%97A
5
67B@"?.A
&@A
".f39.7A]


,.4-3=
3'5'38
-
/'% - 3'
23342
'-
+.-%B3 1,
-4+ .2'
-+.%4 B 31 3 
/3' -32

77I
&!9@@(vZwZxZ
B?9?&
7"-B@=(vZwZ
*55&
9"A&55.vZwZ
59A-.5%&
.,5.vZwZxZ
B%.A-
?&@>B&AvZwZ
65
6&%yZ
?!?
&@A97.vZw
7%
!.&7
9B5.6vZwZxl

v7"&?959,I
&@&?"-
&7A&?
9+
I97Z

vuzwZ
I97Z
?7"&
w5B%&
&?7?%
I97
v
7.F&?@.AIZ
I97Z
?7"&
x&=A959,I
7.AZ
?9.H
9B@@&
9@=.A5Z
9@=."&@
.F.5@
9+
I97Z
I97Z
?7"&
y9F?A.@
-?6"&BA."5@
9?=9?A.97Z
@A
79F&?Z
Z



l
9??&@=97%.7,
BA-9?\
?
!.&7
9B5.6
7"&?
&@&?"-
&7A&?
9+
I97Z

vuzw
vzvZ
"9B?@
5!&?A
-96@
{~uux
I97
?7"&
&5\
„xx
y
|w
{}
v~
|u

v|u


\
@&5.7&
"""\
"9F5&7A5I
"59@&%
".?"B5?

\
"-?97."
-&=A.A.@

F.?B@
-\
-?96A.7
66B79?&".=.AA.97
%%\
%.,.A5
%?9=5&A

\
7%
=9.7A
&,\
&
7A.,&7
\
&=A.A.@

.?B@
\
&=A9"&55B5?
"?".796

\
B67
66B79%&+.".&7"I
.?B@
@\
B"5&9@jAk.%&@
759,B&@
 f\
=&,I5A&%
.7A&?+&?97
=,\
=?&,&796."

>\
>B7A.AA.F&

j=95I6&?@&
"-.7
?&"A.97k
\
955.7,
.?"5&
6=5.+."A.97
?"\
?&5H&%
".?"B5?


v|v


-&
"9F5&7A5I
"59@&%
".?"B5?

j"""k
.7
A-&
7B"5&B@
9+
.7+&"A&%
"&55@
.@
A-&
-556?4
9+
-&=A.A.@

F.?B@
jk
.7+&"A.97]
A@
=&?@.@A&7"&
.7
A-&
-9@A
5.F&?
"97A?.!BA&@
A9
A-&
"-?97.".AI
9+

.7+&"A.97
7%
.@
?&@=97@.!5&
9+
F.?5
?&"A.FA.97
+A&?
A?&A6&7A
G.A-%?G5
9?
?&"9F&?IZ
B7%&?
"&?A.7
"5.7."5
"97%.A.97@]
97,fA&?6
7A.F.?5
A-&?=.&@
"-.&F&
F.?5
@B==?&@@.97
7%
?&
@@9".A&%
A9
%&"?&@&
.7
A-&
"""
=995]
&F&?A-&5&@@Z
A-&I
?&
B7!5&
A9
&5.6.7A&
"""
+?96
A-&
.7+&"A&%
"&55@Z
!BA
&F.%&7A
5.6.AA.97@
.7
A-&
"B??&7A5I
F.5!5&
A&"-7.>B&@
+9?
"""
>B7A.+."A.97
=?&F&7A

"9??&"A
7%
?&5.!5&
%&A&"A.97
9+
"""
.7
F&?I
59GfF.?&6."
@6=5&@]
&
%&697@A?A&
A-A
A-&
B@&
9+
%?9=5&A
%.,.A5

j%%k
=?9F.%&@

B@&+B5
A995
A9
%&A&"A
"""
.7
@6=5&@
A-A
@"9?&%
7&,A.F&
B@.7,
>B7A.AA.F&

7%
?955.7,
".?"5&
6=5.+."A.97
jk]
7

"9-9?A
9+
597,fA&?6
A&5!.FB%.7&
A?&A&%
=A.&7A@Z
%%
559G&%
A9
%&A&"A
7%
>B7A.+I
"""
.7
~}ƒ
.7
A&@A&%
@6=5&@Z
"96=?&%
A9
975I
xuƒ
%&A&"A&%
!I
>]
9?&9F&?Z
"-?96A.7
.66B79=?&".=.AA.97
75I@.@
9+
-.@A97&
=9@AfA?7@5A.975
69%.+."A.97@
@@9".A&%
A9
?&@.%B5
"""
@@9".A&%
A9
%%
.7%."A&@
7
&7?."-6&7A
.7
6?4@
@@9".A&%
A9
?&=?&@@&%
A?7@"?.=A.97Z
=?9F.%.7,Z
+9?
A-&
+.?@A
A.6&Z
%A
97
A-&
&=.,&7&A."
?&,B5A.97
9+
"""
B7%&?
7A.F.?5
A-&?=I
)0
9)91]
5A9,&A-&?Z
G&
,.F&
&F.%&7"&
A-A
A-&
5?,&
639?.AI
9+
fA?&A&%
=A.&7A@
@A.55
-?!9?
>B7A.+.!5&
"""
.7
A-&.?
5.F&?
7%
A-A
.A@
&=.,&7&A."
@AAB@
"9B5%
!&
%.++&?&7A
+?96
A?&A6&7Af71F&
=A.&7A@Z
A-B@
=?9F.%.7,
7&G
479G5&%,&
A-A
"9B5%
-&5=
.7
A-&
&F5BA.97
9+
7&G
"96!.7A9?.5
A-&?=&BA."
@A?A&,.&@]

v|w


569@A
xuu
6.55.97
=&9=5&
G9?5%G.%&
?&
"-?97."55I
.7+&"A&%
G.A-
&=A.A.@

.?B@
jk
7%
"97@&>B&7A5I
&H=9@&%
A9
7
.7"?&@&%
?.@4
9+
".??-9@.@
7%
-&=A9"&55B5?
"?".796
jk
^v]
-&
-556?4
9+

.7+&"A.97
.@
A-&
=?&@&7"&
9+
A-&
"9F5&7A5I
"59@&%
".?"B5?

j"""k
.7
A-&
7B"5&B@
9+
.7+&"A&%
"&55@
^w]
-&
.7A?-&=A."
"""
.@

@A!5&
&=.@965
F.?5
`6.7."-?969@96&aZ
+9?6&%
+A&?
A-&
F.?B@
&7A?I
.7
A-&
-&=A9"IA&]
A
@&?F&@
@
A-&
B7.>B&
A&6=5A&
+9?
55
F.?5
@
=?9%B"A.97Z
"96=?.@&%
A-&
=?&,&796."
j=,k
<sup>wZx</sup>]
-&
=&?@.@A&7"&
9+
"""
.7
A-&
-9@A
5.F&?
"97A?.!BA&@
A9
A-&
"-?97.".AI
9+

.7+&"A.97
7%
.@
?&@=97@.!5&
9+
F.?5
?&"A.FA.97
+A&?
?&"9F&?IZ
B7%&?
"&?A.7
"5.7."5
"97%.A.97@Z
9?
A?&A6&7A
G.A-%?G5
yZz]
&G
A-&?=&BA."
@A?A&,.&@
A?,&A.7,
"""
"97A.7,&7A
9?
.A@
?&=5."A.97
?&
7&&%&%
A9
&?%."A&

.7+&"A.97
7%
AG9
6.7
9!3&"A.F&@
-F&
!&&7
.%&7A.+.&%\
.7A?-&=A."
"""
"5&?7"&
jF.?959,."5
"B?&k
9?
`@.5&7".7,a
j+B7"A.975
"B?&k
{]

B"5&9@jAk.%&@
759,B&@
j@k
?&
A-&
6.7
%?B,@
"B??&7A5I
B@&%
+9?

A?&A6&7A[
A-&I
A?,&A
A-&
F.?5
=95I6&?@&Z
!59"4.7,
=,
?&F&?@&
A?7@"?.=A.97
7%
@9
.7+&"A.9B@
F.?.97
+9?6A.97
x]
5A-9B,-
@
A?&A6&7A@
&7!5&
7
&++.".&7A
"97A?95
9+
F.?5
?&=5."A.97Z
A-&I
-F&
79
%.?&"A
&++&"A
97
"""]

?&=5."A.97
"9B5%
?&@B6&
+A&?
@
"&@@A.97
7%
F.?959,."5
?&5=@&@
?&
9+A&7
9!@&?F&%]

%&"?&@&
9+
"""
69B7A
+A&?
@-9?A
9?
597,
"9B?@&
9+
@
A-&?=I
-@
!&&7
?&=9?A&%
!I
%.++&?&7A
BA-9?@
)0
9)751
7%
)0
9)91Z
&H=5.7&%
!I
A-&
%.5BA.97
9+
A-&
.7A?-&=A."
=995
9+
"""
6&%.A&%
!I
"&55
%.F.@.97@
^xZ|gvx]
7

?&"&7A
@AB%IZ
.
"7
.F
+.5&%
A9
%&A&"A
7I
.7A?-&=A."
"""
+9?
-5+
9+
A-&
yx
=A.&7A@
+A&?
vu
I&?@
9+
@
A?&A6&7AZ
G-&?&@
@96&
9+
A-&
"""f7&,A.F&
@6=5&@
G&?&
=9@.A.F&
+9?
=,
7%
A9A5
.7A?-&=A."


vx]
-&@&
?&@B5A@
>B&@A.97&%
A-&
@&7@.A.F.AI
9+
A-&
"B??&7A
"""
>B7A.+."A.97
A&"-7.>B&@]
-.@
A&"-7."5
.@@B&
.@
"?B".5
@.7"&
A-&
@@&@@6&7A

v|x
9+
7&G
A-&?=&BA."
@A?A&,.&@
A?,&A.7,
F.?959,."5
"B?&Z
A-A
.@

A9
@I
.6.7,
A9
"5&?
"""
G.55
?&>B.?&
A-&
%&F&59=6&7A
9+
?&5.!5&


%&A&"A.97
A&"-7.>B&@Z
%=A&%
A9
)0
9)91
@AB%.&@
7%
A9
A-&
59G
5&F&5@
9+
A9A5

&HA?"A&%
+?96
5.F&?
!.9=@.&@
^{]
9
"-.&F&

+B7"A.975
"B?&Z
A-&?=&BA."
@A?A&,.&@
A?,&A.7,
"""
`@.5&7".7,a
?A-&?
A-7
.A@
&?%."A.97
?&
%&F&59=&%
^{]
-&
F.?5
6.7."-?969@96&
.@
&=.,&7&A."55I
?&,B5A&%
!I
-9@A
7%
F.?5
+"A9?@Z
A-&
F.?5
?&=5."A.97
!&.7,
"A.FA&%
9?
?&=?&@@&%
A
%.++&?&7A
5&F&5@]
-&
"""
&=.,&7&A."
?&,B5A.97
"9B5%
!&
@AB%.&%
!I
-?96A.7
66B79?&".=.AA.97
j-k
7%
A-&
@@&@@6&7A
9+
@@9".A&%
-.@A97&
"&AI5A.97d%&"&AI5A.97Z
6&A-I5A.97
9?

6&A-I5A.97
yZvygv{]

-&
+&@.!.5.AI
7%
.7A&?&@A
9+
&=.,&7&A."
@AB%.&@
!I
-
97
5.F&?
!.9=@.&@
@6=5&@
+?96
@fA?&A&%
=A.&7A@
-@
79A
!&&7
&H=59?&%
7%
A9
9B?
!&@A
479G5&%,&Z
79
%A
-F&
!&&7
?&=9?A&%
?&,?%.7,
&=.,&7&A."
69%.+."A.97@
97
"""
%B?.7,
@
A?&A6&7A]

&
A994
%F7A,&
9+

"9-9?A
9+
z{
=A.&7A@
A?&A&%
+9?
x
A9
z
I&?@
G.A-
A-&
7B"5&9@.%&@
759,B&
&5!.FB%.7&
A9
@AB%I
.7A?-&=A."
F.?5
6?4&?@
)0
9)91Z
G-."-
"9B5%
!&
?&5&F7A
+9?
A-&
@@&@@6&7A
9+
7&G

"B?&
@A?A&,.&@Z
!@&%
97
"""
"5&?7"&
9?
`@.5&7".7,a]
&
?&=9?A&%
7%
"96=?&%
.7A?-&=A."
F.?5

5&F&5@Z
6&@B?&%
!I
%.++&?&7A
A&"-7.>B&@Z
.7"5B%.7,

-.,-
@&7@.A.F&
6&A-9%
559G.7,
59G
5&F&5@
>B7A.+."A.97
7%
@B.A!5&
+9?
)0
9)91
@AB%.&@
.7
A-&
"97A&HA
9+

"B?&
@A?A&,.&@]
&
5@9
?&5A&%
+9?
A-&
+.?@A
A.6&
A-&
&=.,&7&A."
"-?"A&?.@A."@
9+
.7A?-&=A."
"""
+A&?
597,
A&?6
A&5!.FB%.7&
A?&A6&7A
7%
@B,,&@A&%
@96&
&=.,&7&A."
69%B5A.97@
B7%&?
@
A-&?=I]
-&@&
?&@B5A@
!?.7,
7&G
.7@.,-A@
.7A9
A-&
)0
9)91
&++.""I
9+
A-&?=&BA."
@A?A&,.&@
%&F&59=&%
A9
"B?&

.7+&"A.97
!I
A?,&A.7,
&.A-&?
"""
"5&?7"&
9?
`@.5&7".7,a]

v|y




7)"076

Fifty-six patients (46 males and 10 females) from the clinical trial NV-02B-015 (Novartis Pharmaceuticals) were prospectively enrolled for the CLDT600ACN04E1 study, an extension of CLDT600ACN04E study assessing the efficacy and safety in fourth to sixth year of Telbivudine treatment in patients with Chronic Hepatitis B (CHB) (Novartis Pharmaceuticals). New consent was given and the study was approved by the competent ethical committee.


=A.&7A@
-%
"96=5&A&%
x
A9
z
I&?@
9+
&5!.FB%.7&
A-&?=I
""9?%.7,
A9
A-&
NV-02B-015 and CLDT600ACN04E1 clinical trials 7%
A-&
A?&A6&7A
G@
"97A.7B&%]
5.7."5
7%
F.?959,."5
%A
G&?&
"955&"A&%
!&+9?&
!&,.77.7,
9+
A?&A6&7A
j!@&5.7&
jk
9+
NV-02B-015 studyk
7%
A
A-&
&7%
9+
+9559G
B=
j&7%
=9.7A
jk
9+
CLDT600ACN04E1 studyk
jB==5&6&7A?I
.,B?&
vk]
.@A959,I
G@
@@&@@&%
97
5.F&?
A.@@B&
A

7%
5.F&?
!.9=@I
=&?+9?6&%
A

snap frozen at -80°C to subsequent viral markers analysis.

For the study of cccDNA epigenetic regulation features, 7 untreated CHB patients from an historical cohort were used as comparative samples. These 7 CHB patients underwent liver biopsy in the frame of their clinical follow-up and a fragment was preserved for research purpose after patient’s consent and stored at -80°C. The protocol was approved by institutional Ethic Committees.

None of the patients from the clinical trial or the historical cohort presented Human Immunodeficiency Virus (HIV), Hepatitis C virus or Hepatitis Delta virus co-infection.

v|z
&?B6
.?5
9%
jkZ

5&F&5@Z
&,Z
&
7%
@
@&?959,.&@
G&?&
&@A!5.@-&%
A

7%

!I
9F?A.@
-?6"&BA."5@
""9?%.7,
A9
.7A&?7A.975
@A7%?%@]

Intrahepatic total HBV DNA, cccDNA and pgRNA quantification using qPCR method


G@
&HA?"A&%
+?96
@7=f+?9J&7
5.F&?
!.9=@.&@
B@.7,
A-&
@A&?
B?&q

B?.+."A.97
.A
j=."&7A?&pZ
55B6.7p
96=7IZ
%.@97Z
k
""9?%.7,
A9
A-&
67B+"AB?&?_@
.7@A?B"A.97@]
.,-
B?&

?++.7
.A
j9"-&p
.+&
".&7"&Z
7%.7=95.@Z
k
G@
B@&%
+9?

&HA?"A.97]
Quantity and integrity of the extracted DNA and RNA were assessed by NanoDrop™ Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Patients’ samples were run in duplicate and in two independent experiments. B7A.AA.F&

G&?&
=&?+9?6&%
B@.7,
@=&".+."
=?.6&?@
7%
+5B9?&@"&7"&
-I!?.%.JA.97
=?9!&@
=?&F.9B@5I
%&@"?.!&%

Dans le document De la détection de l'ADNccc par de nouvelles technologies à la preuve de concept de sa dégradation à visée thérapeutique dans des modèles d'infection par le virus de l'hépatite B (Page 158-189)